Microbot jumps on successful pre-clinical study of robotic surgical system
17/10/2023 15:50
** Shares of medical device manufacturer Microbot Medical
MBOT.O rise ~18% to $1.50, on track to its biggest rise in
four months
** Co says its LIBERTY Robotic Surgical System performed
with 100% usability and technical success without any adverse
events in a pre-clinical study testing the system in animals
** Says the system aims to improve the way surgical robotics
are used in endovascular procedures - the treatment of blood
vessel conditions with minimal invasion
** MBOT plans on submitting an Investigational Device
Exemption (IDE) application to the FDA to commence its clinical
trial in humans
** IDE allows an investigational device to be used in a
clinical study to collect safety and effectiveness data
** Including session's move, shares down ~51.2% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on Microbot Medical
See all newsBrief: Microbot Medical® Enters Into An Agreement To Expand Access For America’S Veteran And Military Patient Populations
Microbot Medical rises as U.S. federal supply deal expands reach of robotic surgical device
Brief: Microbot Medical Recorded Revenue During Its Quarter Ended March 31, Benefiting From Limited Market Release Of Liberty System
Brief: Microbot Medical®’S Liberty® Endovascular Robotic System Is Now Adopted By Multiple Accounts Across Key Territories Including Two Access-Pvi Pivotal Clinical Trial Sites
Brief: Microbot Medical Continues Its 2025 Momentum Announces Key 2026 Milestones